Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cyfuse Biomedical K.K. specializes in 3D bioprinting technology for regenerative medicine, focusing on creating tissue constructs for therapeutic applications. The company operates primarily in Japan, leveraging its proprietary technology to differentiate itself in the competitive landscape of drug manufacturers.
Cyfuse generates revenue through its innovative 3D bioprinting services, which are utilized in research and therapeutic applications. The company benefits from strong pricing power due to its unique technology that allows for the creation of complex tissue structures, setting it apart from traditional methods.
Advancements in 3D bioprinting technology and successful clinical trials
Partnerships with pharmaceutical companies for drug development
Regulatory approvals for new bioprinted products
Changes in healthcare policies affecting regenerative medicine funding
Technological disruption from emerging bioprinting competitors
Regulatory changes impacting the approval process for bioprinted products
Increased competition from established pharmaceutical companies entering the bioprinting space
Potential for new entrants with innovative technologies
Negative operating cash flow and free cash flow could limit future growth investments
High operating margin volatility due to R&D expenditures
moderate - The company's performance is somewhat linked to healthcare spending, which can be influenced by economic cycles.
Interest rates affect the company's cost of capital and funding for R&D projects, potentially impacting growth investments.
minimal - The company has a manageable debt-to-equity ratio of 0.45, indicating limited reliance on external credit.
growth - Investors seeking exposure to innovative healthcare technologies and potential high returns from successful product commercialization.
high - The stock has shown significant price fluctuations, as evidenced by a 42.6% decline over the past year.